In November 2007, Neurimmune entered into an agreement with Biogen, a leading biopharmaceutical company to develop and commercialize novel treatments for Alzheimer’s disease with an aggregate deal volume of $386 million plus royalties on net sales.
In 2010, Neurimmune entered into a second deal with Biogen, with an additional aggregate volume of more than $430 million for the worldwide rights to three immunotherapy programs addressing alpha-synuclein, tau and TDP-43. These are believed to be central targets for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
In 2013, Neurimmune and ALS Therapy Development Institute in Cambridge, MA, partnered to advance treatments in ALS. The research partnership explores Neurimmune’s human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1) and the advancement into clinical development.
Besides the CNS programs, Neurimmune continues to extend and apply its RTM™ technology platform to identify prime therapeutic antibody candidates in therapeutic areas with a high unmet medical need. These drugs shall be advanced by the company and partnered with the biopharmaceutical industry to utilize complimentary resources and capabilities for drug development and to increase Neurimmune’s sustainable revenue stream.